2025-05-24 - Analysis Report
Okay, here's the analysis of TG Therapeutics Inc (TGTX), focusing on the provided data and incorporating the requested elements.

**Report on TG Therapeutics Inc (TGTX)**

**Company Overview:** TG Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases.

**1. Performance vs. S&P 500 (VOO)**

*   **TGTX Cumulative Return:** 65.97%
*   **VOO Cumulative Return:** 79.45%
*   **Absolute Divergence (Current):** -13.5
*   **Relative Divergence:** 20.0 (Indicates TGTX is currently positioned at the 20th percentile relative to its historical divergence range from VOO)

    *Analysis:* TGTX has underperformed the S&P 500 over the period. The Relative Divergence suggests the current underperformance is near the lower end of its historical range compared to VOO.

*   **Alpha, Beta Analysis**

| Year       | CAGR    | MDD   | Alpha   | Beta   | Cap(B) |
| :----------- | :------ | :------ | :------ | :----- | :------- |
| 2015-2017  | -6.0%   | 56.5%   | -35.0%  | -0.1   | 1.3      |
| 2016-2018  | -8.0%   | 58.6%   | -26.0%  | -0.0   | 0.7      |
| 2017-2019  | 74.0%   | 58.6%   | 44.0%   | -0.0   | 1.8      |
| 2018-2020  | 402.0%  | 58.6%   | 377.0%  | -0.1   | 8.3      |
| 2019-2021  | 125.0%  | 63.5%   | 70.0%   | -0.2   | 3.0      |
| 2020-2022  | -76.0%  | 70.4%   | -82.0%  | -0.3   | 1.9      |
| 2021-2023  | -350.0% | 70.4%   | -367.0% | -0.8   | 2.7      |
| 2022-2024  | 71.0%   | 73.1%   | 54.0%   | -1.0   | 4.8      |
| 2023-2025  | 73.0%   | 84.7%   | 46.0%   | 0.3    | 5.5      |

*Analysis:* The table reveals:

*   **Highly Variable Returns:** CAGR ranges widely, from -350% to 402%, indicating high volatility.
*   **High Maximum Drawdown (MDD):**  MDD consistently high, suggesting significant risk.
*   **Inconsistent Alpha:** Alpha fluctuates, reflecting periods of both outperformance and underperformance relative to the benchmark.
*   **Low or Negative Beta:** The beta is generally low and often negative, suggesting a weak or inverse correlation with the S&P 500. This could imply that TGTX's price movements are not strongly tied to the broader market.

**2. Recent Price Action**

*   **Current Price:** \$34.57
*   **Previous Close:** \$34.24
*   **Change:** 0.96%
*   **5-Day Moving Average:** \$34.69
*   **20-Day Moving Average:** \$36.91
*   **60-Day Moving Average:** \$37.98

*Analysis:* The stock is trading below both its 20-day and 60-day moving averages, suggesting a short-term downtrend. The recent price increase of 0.96% from the previous close is a positive sign, but it's not enough to reverse the downtrend.

**3. Technical Indicators**

*   **Market Risk Indicator (MRI):** 0.366 (Low Risk)
*   **RSI:** 35.53 (Oversold)
*   **PPO:** -0.37
*   **20-Day Relative Divergence Change:** 0.9 (Short-term increase)
*   **Expected Return:** -195.3%

*Analysis:*

*   **MRI:** Indicates a low level of overall market risk.
*   **RSI:** An RSI below 30 is generally considered oversold, suggesting the stock may be undervalued and could experience a bounce.
*   **PPO:** Negative PPO implies that the short-term moving average is below the long-term moving average.
*   **20-Day Relative Divergence Change:** The recent increase suggests a short-term upward movement in relation to the S&P 500.
*   **Expected Return:** The significantly negative expected return is a major red flag, suggesting substantial potential underperformance compared to the S&P 500 in the long term.

**4. Recent News & Significant Events**

*   **Business Developments/Regulatory Changes/Market Events:** Recent developments affecting TGTX.
*   **Analyst Discussions:** Performance and outlook being discussed in the context of industry and global factors.
*   **Stock Volatility:**  Stock showing notable volatility influenced by news, earnings, and executive actions.
*   **Risk & Opportunities:** Experts highlight both risks and opportunities, advising monitoring of news and company announcements.

*Analysis:* The news indicates increased attention on TGTX due to recent developments, volatility, and analyst discussions. Investors should carefully monitor company announcements and news for potential catalysts.

**5. Recent Earnings Analysis**

| Date       | EPS   | Revenue      |
| :----------- | :---- | :------------- |
| 2025-05-09 | 0.03  | 0.12 B$     |
| 2024-11-07 | 0.03  | 0.08 B$     |
| 2024-08-09 | 0.05  | 0.07 B$     |
| 2024-05-06 | -0.07 | 0.06 B$     |
| 2025-05-09 | -0.07 | 0.06 B$     |

*Analysis:*

*   **Mixed Earnings:** EPS has fluctuated between positive and negative values in recent quarters.
*   **Revenue Growth:** Revenue shows a general upward trend over the analyzed period, indicating potential business expansion.

**6. Financial Information**

**Revenue and Profitability:**

| Quarter      | Revenue  | Profit Margin |
| :----------- | :------- | :------------ |
| 2025-03-31 | $0.12B | 87.14%       |
| 2024-12-31 | $0.11B | 85.77%       |
| 2024-09-30 | $0.08B | 88.86%       |
| 2024-06-30 | $0.07B | 88.70%       |
| 2024-03-31 | $0.06B | 91.43%       |

**Capital and Profitability:**

| Quarter      | Equity   | ROE       |
| :----------- | :------- | :-------- |
| 2025-03-31 | $0.24B | 2.13%     |
| 2024-12-31 | $0.22B | 10.49%    |
| 2024-09-30 | $0.19B | 2.02%     |
| 2024-06-30 | $0.18B | 3.87%     |
| 2024-03-31 | $0.16B | -6.69%    |

*Analysis:*

*   **Growing Revenue:** Revenue has been increasing consistently over the quarters.
*   **High Profit Margins:** Profit margins are very high, suggesting strong pricing power or efficient cost management.
*   **Increasing Equity:** Equity has been steadily increasing, indicating a growing capital base.
*   **Fluctuating ROE:** ROE has fluctuated, with a significant peak in 2024-12-31. The most recent ROE is relatively low.

**7. Overall Analysis & Summary**

TG Therapeutics Inc (TGTX) presents a mixed picture:

*   **Underperformance:** TGTX has underperformed the S&P 500, and the negative expected return raises serious concerns about long-term prospects.
*   **Volatility:** The stock is highly volatile, as evidenced by the wide range of CAGR values and high MDD.
*   **Positive Financial Trends:** Revenue and equity have been growing, and profit margins are high, which are positive signs.
*   **Technical Signals:** The stock is currently in a short-term downtrend but may be oversold, potentially leading to a short-term bounce.
*   **News and Events:** Recent news suggests the company is experiencing significant developments and increased attention, which could be a catalyst for future price movements.

*   **In conclusion, based on the provided data, TGTX appears to be a high-risk, high-reward investment. While there are positive financial trends, the underperformance compared to the S&P 500, the negative expected return, and the stock's volatility warrant caution. Investors should carefully monitor company news and announcements and consider their risk tolerance before investing.**
